JP2022543679A5 - - Google Patents
Info
- Publication number
- JP2022543679A5 JP2022543679A5 JP2022507799A JP2022507799A JP2022543679A5 JP 2022543679 A5 JP2022543679 A5 JP 2022543679A5 JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022543679 A5 JP2022543679 A5 JP 2022543679A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019099754 | 2019-08-08 | ||
| CNPCT/CN2019/099754 | 2019-08-08 | ||
| PCT/US2020/045410 WO2021026454A1 (en) | 2019-08-08 | 2020-08-07 | Method of treating cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022543679A JP2022543679A (ja) | 2022-10-13 |
| JP2022543679A5 true JP2022543679A5 (https=) | 2023-08-10 |
| JPWO2021026454A5 JPWO2021026454A5 (https=) | 2023-08-10 |
| JP7526783B2 JP7526783B2 (ja) | 2024-08-01 |
Family
ID=72234946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507799A Active JP7526783B2 (ja) | 2019-08-08 | 2020-08-07 | 癌を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210038578A1 (https=) |
| EP (1) | EP4009969A1 (https=) |
| JP (1) | JP7526783B2 (https=) |
| KR (1) | KR20220047589A (https=) |
| CN (1) | CN114080225A (https=) |
| AU (1) | AU2020327022B2 (https=) |
| BR (1) | BR112022001508A2 (https=) |
| CA (1) | CA3148115A1 (https=) |
| IL (1) | IL289811A (https=) |
| MX (1) | MX2022001450A (https=) |
| TW (1) | TWI857119B (https=) |
| WO (1) | WO2021026454A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7010330B1 (en) | 2003-03-01 | 2006-03-07 | Theta Microelectronics, Inc. | Power dissipation reduction in wireless transceivers |
| US20250032504A1 (en) * | 2021-11-27 | 2025-01-30 | Transthera Sciences (Nanjing), Inc. | Novel application of kinase inhibitor |
| US20250177352A1 (en) | 2022-03-14 | 2025-06-05 | Laekna Limited | Combination treatment for cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| GB2265624B (en) | 1992-03-31 | 1995-04-19 | British Tech Group | 17-substituted steroids useful in cancer treatment |
| MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US20110288142A1 (en) * | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| UY32730A (es) * | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| RU2014154009A (ru) * | 2012-06-06 | 2016-08-10 | Новартис Аг | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания |
| ES3063787T3 (en) * | 2013-10-01 | 2026-04-20 | Novartis Ag | Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor |
| US10265329B2 (en) * | 2015-03-06 | 2019-04-23 | The Cleveland Clinic Foundation | Altering steroid metabolism for treatment of steroid-dependent disease |
-
2020
- 2020-08-07 CA CA3148115A patent/CA3148115A1/en active Pending
- 2020-08-07 BR BR112022001508A patent/BR112022001508A2/pt unknown
- 2020-08-07 CN CN202080048545.3A patent/CN114080225A/zh active Pending
- 2020-08-07 MX MX2022001450A patent/MX2022001450A/es unknown
- 2020-08-07 WO PCT/US2020/045410 patent/WO2021026454A1/en not_active Ceased
- 2020-08-07 EP EP20761400.9A patent/EP4009969A1/en active Pending
- 2020-08-07 KR KR1020227007678A patent/KR20220047589A/ko active Pending
- 2020-08-07 AU AU2020327022A patent/AU2020327022B2/en active Active
- 2020-08-07 JP JP2022507799A patent/JP7526783B2/ja active Active
- 2020-08-07 TW TW109126973A patent/TWI857119B/zh active
- 2020-08-07 US US16/987,924 patent/US20210038578A1/en not_active Abandoned
-
2022
- 2022-01-12 IL IL289811A patent/IL289811A/en unknown
-
2024
- 2024-12-04 US US18/968,073 patent/US20250090514A1/en active Pending